Overview

E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Status:
Active, not recruiting

Trial end date:
2023-10-01

Target enrollment:

Participant gender:

Summary

This research study is aimed to determine the proportion of high risk smoldering multiple myeloma patients who are progression free at 2 years after receiving elotuzumab, lenalidomide and dexamethasone combination therapy.

Phase:

Phase 2

Details

Lead Sponsor:

Dana-Farber Cancer Institute

Collaborators:

Blood Cancer Research Partnership
Bristol-Myers Squibb
Celgene
Multiple Myeloma Research Consortium
The Leukemia and Lymphoma Society

Treatments:

BB 1101
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Elotuzumab
Lenalidomide
Thalidomide